ECP联合甲氧沙林一线治疗中重度cGVHD的随机对照研究
这项1期/先导性随机前瞻性研究纳入新发中重度cGVHD成人患者,1:1随机接受26周SoC+ECP或单纯SoC。第28周意向治疗人群ORR在SoC+ECP组为74.1%、SoC组为60.9%;SoC组生活质量下降而SoC+ECP组保持不变。未发现与ECP设备或甲氧沙林相关的TEAE或SAE。
要点
- 第28周ITT人群ORR:SoC+ECP组74.1% vs SoC组60.9%。
- 研究者评估ORR:SoC+ECP组56.0% vs SoC组66.7%。
- SoC组生活质量在研究期间下降,SoC+ECP组保持不变。
核心结论
- 该研究短期的 encouraging 结果可为后续研究设计提供参考。
- 未发现与ECP设备或甲氧沙林相关的TEAE或SAE。
研究设计与样本
- 这是一项1期/先导性随机、前瞻性研究,首次探讨ECP作为cGVHD一线治疗,基于2015年NIH共识标准诊断和评估反应。
- 2011至2015年间纳入新发(造血干细胞移植后≤3年)中重度cGVHD成人患者,1:1随机接受26周SoC+ECP或SoC(皮质类固醇和环孢素A/他克莫司)。
- 共60例患者随机,ITT人群53例(SoC+ECP组29例;SoC组24例)。
主要发现
- 第28周ITT人群ORR:SoC+ECP组74.1% vs SoC组60.9%。
- 研究者评估ORR:SoC+ECP组56.0% vs SoC组66.7%。
- SoC组患者在28周研究期间生活质量下降,SoC+ECP组患者生活质量保持不变。
- SoC+ECP组最常见TEAE为高血压(31.0%)、咳嗽(20.7%)、呼吸困难(17.2%)和乏力(17.2%)。
- 17例患者(SoC+ECP组8例;SoC组9例)发生35起SAE。
关键数值与推荐
- 主要终点为第28周意向治疗人群的ORR,定义为完全或部分缓解。
- 其他结局包括生活质量指标和安全性。
- 未发现与ECP设备或甲氧沙林相关的TEAE或SAE。
临床怎么用
- 该研究为ECP作为cGVHD一线治疗的随机前瞻性研究,其短期结果可为后续研究设计提供参考。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The investigation of extracorporeal photopheresis (ECP) plus standard of care (SoC) (SoC+ECP) in chronic graft-versus-host disease (cGVHD) within prospective, randomized clinical studies is limited, despite its frequent clinical use. This phase 1/pilot study was the first randomized, prospective study to investigate ECP use as first-line therapy in cGVHD, based on the 2015 National Institutes of Health (NIH) consensus criteria for diagnosis and response assessment. Adult patients with new-onset (≤3 years of hematopoietic stem cell transplantation) moderate or severe cGVHD were randomized 1:1 to 26 weeks of SoC+ECP vs SoC (corticosteroids and cyclosporine A/tacrolimus) between 2011 and 2015. The primary endpoint was overall response rate (ORR), defined as complete or partial response, at week 28 in the intention-to-treat population (ITT). Other outcomes included quality of life (QoL) measures and safety. Sixty patients were randomized; ITT included 53 patients (SoC+ECP: 29; SoC: 24). Week 28 ORR was 74.1% (SoC+ECP) and 60.9% (SoC). Investigator-assessed ORR was 56.0% (SoC+ECP) and 66.7% (SoC). Patients treated with SoC experienced a decline in QoL over the 28-week study period; QoL remained unchanged in SoC+ECP patients. Most frequent treatment-emergent adverse events (TEAEs) in SoC+ECP patients were hypertension (31.0%), cough (20.7%), dyspnea (17.2%), and fatigue (17.2%). Seventeen patients (SoC+ECP: 8; SoC: 9) experienced 35 serious adverse events (SAEs). No TEAEs or SAEs were considered related to the ECP instrument or methoxsalen. The encouraging short-term results of this study could inform the design of subsequent studies. This trial was registered at www.clinicaltrials.gov as #NCT01380535.
引用
- Jagasia M, Scheid C, Socié G, et al. Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD. Blood Adv. 2019. PMID: 31332045. doi:10.1182/bloodadvances.2019000145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。